Matthew W. Davis - 10 Nov 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 11:17:21 UTC
Prior SEC filing
11 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Thomas Zalewski, as Attorney-In-Fact
Filing notes and source

Key filing fact

Matthew W. Davis filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 12 Nov 2026.

Key facts

  • This page summarizes Matthew W. Davis's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2026, 11:17.

Change

  • Previous filing in this sequence was filed on 11 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002094283 Primary reporting owner

Davis Matthew W.

Relationship
Chief Development Officer
Address
C/O AQUESTIVE THERAPEUTICS, INC., 184 LIBERTY CORNER DRIVE, SUITE 305, WARREN
Signature
/s/ Thomas Zalewski, as Attorney-In-Fact
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Tax liability

Transaction value
Shares
-5,303
Change %
-5.3%
Price
$3.52*
Shares after
94,697
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .